Alendronate a promising / multi aspect drug in the management of ostoeoporosis. | [Pakistan Journal of Pharmacology • 2011]

Author(s):

1. Shehla Shaheen: Department of Pharmacology, Ziauddin Medical College, Ziauddin University, Shahrah-e-Ghalib, Block-6 Clifton Karachi-76500, Pakistan

2. Qamaruddin Barakzai: Department of Pharmacology, Ziauddin Medical College, Ziauddin University, Shahrah-e-Ghalib, Block-6 Clifton Karachi-76500, Pakistan

3. Syed Shahid Noor: Department of Orthopaedic, Liaquat National Hospital and Medical College, Karachi, Pakistan

4. Mansoor Ali Khan: Indus Hospital, Karachi, Pakistan

Abstract:

Recently, osteoporosis is regarded as a major health concern due to increase in its incidence, associated morbidities and mortalities. Among antiresorptives, alendronate which is a bisphosphonate is FDA (Food and Drug Administration) approved drug of choice for postmenopausal and glucorticoid induced osteoporosis. It has been also recommended for the prevention of bone loss in perimenopausal women. Currently, it has been also viewed as a treatment option in osteoporotic males. Several clinical trials have highlighted the significant role of alendronate in the management of osteoporosis. Although it was proved to be a safe drug for longer time periods but very recently some studies have reported the risk of low energy subtrochanteric and diaphyseal femoral shaft fractures in the chronic users of alendronate. The current review is undertaken to elaborate the different aspects related to this drug in the scenario of osteoporosis management.

Page(s): 51-66

DOI: DOI not available

Published: Journal: Pakistan Journal of Pharmacology, Volume: 28, Issue: 1, Year: 2011

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views